The company operates as a small-scale enterprise primarily engaged in real estate development and civil construction, while recently diversifying into e-commerce trading for pharmaceutical and healthcare products.
The company lacks a durable competitive advantage, evidenced by highly volatile and often negative net margins and a very low average ROE. Its small scale and lack of specialized assets or brand power leave it vulnerable to market fluctuations and larger competitors.
Capital has been primarily deployed into inter-corporate deposits and loans to related parties rather than reinvestment in core operations. This strategy has resulted in inconsistent returns and a lack of organic growth in the primary business.
The investment collapsed as the company's core operations remained a hollow shell, serving primarily as a conduit for capital to flow into related-party entities. The pivot into pharmaceutical e-commerce failed to gain traction against entrenched competitors, while the large inter-corporate deposits to Sankalp Capital became unrecoverable. As the revolving door of key managerial personnel continued, oversight failed entirely, and the lack of organic cash flow eventually forced a liquidity crisis that wiped out minority shareholders.
RichFakir rates Shricon Industries Ltd's business quality as poor — 34/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Shricon Industries Ltd is trading about 13% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Shricon Industries Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Shricon Industries Ltd's fair value is about ₹74 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →